A new medication for multiple sclerosis, Ocrevus (ocrelizumab), is now available to multiple sclerosis patients.
The multiple sclerosis (MS) community has been busy talking about the recently FDA-approved drug Ocrevus (ocrelizumab). It’s been proven to slow down the progression of the disease, but what else do we know about this much buzzed-about drug? Here are some quick facts about Ocrevus according to the Multiple Sclerosis Society.
When it was approved: March 28. Ocrevus is a drug used for the treatment of relapsing-remitting multiple sclerosis (RRMS) and the first treatment available for primary-progressive multiple sclerosis (PPMS).
How it’s taken: The drug is to be taken via an IV infusion every six months. The first dose is given in two stages a fortnight apart.
Who can take it: Ocrevus has not been tested on children and is only for the treatment of adults with PPMS and RRMS.
How it works: Ocrevus targets certain B-cells in the blood which are responsible for demyelination.
How do we know? Clinical trials with PPMS patients showed that those taking the drug experienced a 24 percent reduction in disease progression and a decrease in a number of brain lesions. Clinical trials with RRMS patients showed a 47 percent decrease in relapses compared to patients taking Rebif and up to 95 percent reduction in active inflammation.
How much it’ll cost: The yearly cost of Ocrevus treatment will be $65,000, which patients should be able to get covered by their medical insurance.
Read full article: Ocrevus Approval: A Quick Cheat Sheet – Multiple Sclerosis News Today
|Read Full Article: Ocrevus Approval: A Quick Cheat Sheet – Multiple Sclerosis News Today|